Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Liabilities and Shareholders Equity (2020 - 2025)

Bolt Biotherapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $65.1 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 40.5% year-over-year to $65.1 million; the TTM value through Sep 2025 reached $326.0 million, down 39.19%, while the annual FY2024 figure was $99.6 million, 37.65% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $65.1 million at Bolt Biotherapeutics, down from $75.5 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $347.1 million in Q2 2021 and bottomed at $65.1 million in Q3 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $190.7 million (2023), against an average of $198.1 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 561.16% in 2021 before it plummeted 40.5% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $307.7 million in 2021, then dropped by 25.97% to $227.8 million in 2022, then fell by 29.86% to $159.8 million in 2023, then plummeted by 37.65% to $99.6 million in 2024, then crashed by 34.71% to $65.1 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Liabilities and Shareholders Equity are $65.1 million (Q3 2025), $75.5 million (Q2 2025), and $85.9 million (Q1 2025).